Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Alm

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
ACS Infectious Diseases|March 24, 2020
Innovation in Antimicrobial Resistance: The CARB-X PerspectiveRichard A Alm, Karen Gallant
Current Drug Targets. Infectious Disorders|February 7, 2003
Novel intervention strategies for Helicobacter pylori treatmentBrian Noonan, Richard A Alm
The Journal of Antimicrobial Chemotherapy|August 6, 2016
Identification of non-PBP2a resistance mechanisms in Staphylococcus aureus after serial passage with ceftaroline: involvement of other PBPsSushmita D Lahiri, Richard A Alm
Journal of Clinical Microbiology|July 3, 2015
Ceftaroline Activity against mecC-Containing Staphylococcus aureusSushmita D Lahiri, Richard A Alm
Antibiotics (Basel, Switzerland)|July 26, 2020
Narrow-Spectrum Antibacterial Agents-Benefits and ChallengesRichard A Alm, Sushmita D Lahiri
The Journal of Antimicrobial Chemotherapy|October 21, 2015
Potential of Staphylococcus aureus isolates carrying different PBP2a alleles to develop resistance to ceftarolineSushmita D Lahiri, Richard A Alm
Antimicrobial Agents and Chemotherapy|March 2, 2016
Identification of Novel VEB β-Lactamase Enzymes and Their Impact on Avibactam InhibitionSushmita D Lahiri, Richard A Alm
Plos One|July 30, 2020
A novel pre-clinical antibacterial pipeline databaseSarah Paulin, Richard A Alm, Peter Beyer
The Journal of Antimicrobial Chemotherapy|January 31, 2015
Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3Richard A Alm, Michele R Johnstone, Sushmita D Lahiri
Antimicrobial Agents and Chemotherapy|June 17, 2015
Insights into the mechanism of inhibition of novel bacterial topoisomerase inhibitors from characterization of resistant mutants of Staphylococcus aureusSushmita D Lahiri, Amy Kutschke, Kathy McCormack, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
ACS Infectious Diseases|March 24, 2020
Innovation in Antimicrobial Resistance: The CARB-X PerspectiveRichard A Alm, Karen Gallant
Current Drug Targets. Infectious Disorders|February 7, 2003
Novel intervention strategies for Helicobacter pylori treatmentBrian Noonan, Richard A Alm
The Journal of Antimicrobial Chemotherapy|August 6, 2016
Identification of non-PBP2a resistance mechanisms in Staphylococcus aureus after serial passage with ceftaroline: involvement of other PBPsSushmita D Lahiri, Richard A Alm
Journal of Clinical Microbiology|July 3, 2015
Ceftaroline Activity against mecC-Containing Staphylococcus aureusSushmita D Lahiri, Richard A Alm
Antibiotics (Basel, Switzerland)|July 26, 2020
Narrow-Spectrum Antibacterial Agents-Benefits and ChallengesRichard A Alm, Sushmita D Lahiri
The Journal of Antimicrobial Chemotherapy|October 21, 2015
Potential of Staphylococcus aureus isolates carrying different PBP2a alleles to develop resistance to ceftarolineSushmita D Lahiri, Richard A Alm
Antimicrobial Agents and Chemotherapy|March 2, 2016
Identification of Novel VEB β-Lactamase Enzymes and Their Impact on Avibactam InhibitionSushmita D Lahiri, Richard A Alm
Plos One|July 30, 2020
A novel pre-clinical antibacterial pipeline databaseSarah Paulin, Richard A Alm, Peter Beyer
The Journal of Antimicrobial Chemotherapy|January 31, 2015
Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3Richard A Alm, Michele R Johnstone, Sushmita D Lahiri
Antimicrobial Agents and Chemotherapy|June 17, 2015
Insights into the mechanism of inhibition of novel bacterial topoisomerase inhibitors from characterization of resistant mutants of Staphylococcus aureusSushmita D Lahiri, Amy Kutschke, Kathy McCormack, et al.
Pageof 5